Momenta Pharmaceuticals Inc (MNTA)

NASDAQ
52.48
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    52.46 - 52.53

MNTA Overview

Prev. Close
52.48
Day's Range
52.46-52.53
Revenue
6.61M
Open
52.47
52 wk Range
26.87-52.53
EPS
-2.12
Volume
0
Market Cap
6.24B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
845,363
P/E Ratio
-
Beta
1.71
1-Year Change
77.96%
Shares Outstanding
118,965,224
Next Earnings Date
Oct 28, 2021
What is your sentiment on Momenta Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Momenta Pharmaceuticals Inc News

Momenta Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary

Momenta Pharmaceuticals Inc Company Profile

Momenta Pharmaceuticals Inc Company Profile

Employees
118

Momenta Pharmaceuticals, Inc., a biotechnology company, discovers and develops novel therapeutics for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy; and M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity. The company’s biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. Momenta Pharmaceuticals, Inc. has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. Momenta Pharmaceuticals, Inc. was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. The company operates as a subsidiary of Johnson & Johnson.

Read More
  • 📉
    0
    • So tomorrow a big drop?
      0
      • no. JNJ acquired them for 6.5 mill. in a straight cash transaction.
        0
    • what's has happened?
      0
      • Acquired.
        1
        • Drop a lot?
          0
          • Improving EPS and Revenues for MNTA. Nice looking up trend on the weekly, but must break through Resistance above closing price of $17 before i buy in. Looking at low 20's in the next few weeks if it breaks through.
            0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.